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Abstract9
The prevalence of asthma and allergic disease has increased in many countries and there has been speculation that immunization promotes
allergic sensitization. Bordetella pertussis infection exacerbates allergic asthmatic responses. We investigated whether whole-cell pertussis
vaccine (Pw) enhanced or prevented B. pertussis induced exacerbation of allergic asthma. Groups of mice were immunized with Pw, infected
w
o
a
i
e
o
r
10
11
12
13
14
15
16
17
18
19
©20
K21
22
123
24
c25
u26
d27
w28
s29
s30
o31
i32
c33
t34
a35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
1 0
2 d CO
RR
EC
TE
D 
PR
OO
ith B. pertussis and/or sensitized to ovalbumin. Immunological, pathological and physiological changes were measured to assess the impact
f Pw immunization on immune deviation and airway function. Pw immunization modulated ovalbumin-specific serum IgE production,
nd reduced local and systemic IL-13 and other cytokine responses to sensitizing allergen. Histopathological examination revealed Pw
mmunization reduced the severity of airway pathology and decreased bronchial hyperreactivity to methacholine exposure. Pw does not
nhance airway IL-13 and consequently does not enhance but protects against the exacerbation of allergic responses. We find no evidence
f Pw contributing to allergic asthma, but rather provide evidence of a mechanism whereby whole-cell pertussis vaccination has a protective
ole.
2004 Elsevier B.V. All rights reserved.
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. Introduction
Asthma is a chronic disease of the respiratory tract of in-
reasing prevalence in developed societies [1]. The current
nderstanding of allergic asthma is that it results from a break-
own in the normal tolerance to inhaled antigens, associated
ith Th2 cytokine production [2,3]. The inflammatory re-
ponse in asthma is tightly associated with airway hyperre-
ponsiveness, increased mucus production and an infiltration
f the bronchial mucosa with CD4+ T-cells [4]. There is ev-
dence of an altered local T-cell response in favour of Th2
ytokine release (IL-4, IL-5 and IL-13) resulting in B-cell iso-
ype switching to IgE, recruitment of eosinophils, basophils
nd mast cells and production of inflammatory mediators [5].
∗ Corresponding author. Tel.: +353 1 7083835; fax: +353 1 7086337.
E-mail address: bpmahon@may.ie (B.P. Mahon).
The murine OVA model of airway hyperresponsiveness ex-
hibits many of the features of human asthma, including air-
way hyperreactivity, inflammation and increased serum IgE
levels [6,7]. Th2 cells secreting IL-4, IL-5, and IL-13 play a
central role in initiating and sustaining the asthmatic response
in this model [8]. While Th2 cells promote airway inflamma-
tion in asthma, it has been proposed that Th1 cells protect
against allergic disease by antagonizing Th2 activity. Infec-
tious diseases that induce Th1 type responses, might hamper
the development of allergen-specific Th2 cells and prevent
allergy [9].
Epidemiological and clinical studies have suggested a link
between the relative absence of infectious diseases and the
increase in allergic disorders [10,11]; this is referred to as the
‘hygiene hypothesis’. It predicts that infections prevent the in-
duction of allergen-specific Th2 cells through antagonism or
the induction of regulatory T-cells, particularly during neona-
165-2478/$ – see front matter © 2004 Elsevier B.V. All rights reserved.
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tal and early childhood development [10,12]. However, there53
are data that confound this interpretation, increased IFN-54
is seen in asthmatic patients compared with normal subjects55
[3,13]. Allergen-specific Th1 cells also fail to counteract air-56
way hyperresponsiveness in murine models [14]. Further-57
more, several studies have suggested that viral/bacterial in-58
fections do not protect but exacerbate disease. Respiratory59
syncytial virus, commonly associated with lower lung in-60
fections in infancy, is known to exacerbate asthma [15,16].61
As does Bordetella pertussis [17]. Consequently, competing62
interpretations for the pathogenesis of asthma have been pro-63
posed [18,19].64
B. pertussis is a Gram-negative bacterium and the65
causative agent of pertussis or “whooping cough”, a respi-66
ratory disease that remains a significant cause of morbidity67
and mortality in infants worldwide. It is a highly contagious68
disease, and can occur at any age, though severe illness is69
more common in young un-immunized children. B. pertussis70
infection induces Th1 responses [20,21] and can be mod-71
elled by respiratory challenge of mice, which correlates well72
to responses in humans [22].73
There has been speculation about the possible promotion74
of allergy by common childhood vaccinations [23,24]. A75
substantial proportion of children predisposed to allergy and76
asthma may not be fully immunized because of public appre-77
hension surrounding immunization [25]. A number of stud-78
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lergic asthma [17] and we have previously shown that Pw 109
immunization induces a similar immune response to infec- 110
tion [34] and that although variables such as route, dose 111
and timing influence T-cell responses in animal models, Pw 112
is a consistent inducer of Th1 responses [20]. In order to 113
test whether immunization with Pw exacerbated asthma, we 114
employed a well-characterized murine model of whole-cell 115
pertussis vaccination and B. pertussis infection in combina- 116
tion with the murine OVA model of airway hyperresponsive- 117
ness. We show that although Pw induces a Th1 type im- 118
mune response to B. pertussis infection, it does not exac- 119
erbate pathology in a model of allergic asthma. Our find- 120
ings demonstrate that Pw immunization prevents B. pertus- 121
sis enhancement of OVA-induced IL-10 and IL-13, which 122
results in a subsequent decrease in airway hyperresponsive- 123
ness and pathology. This study finds no evidence of a mech- 124
anism to support speculation linking Pw immunization and 125
asthma. 126
2. Materials and methods 127
2.1. Animals and experimental approach 128
Six- to 8-week-old female BALB/c (Harlan, UK) mice 129
were used under the guidelines of the Irish Department 130
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es have analysed the prevalence of allergic sensitization and
topic disease in relation to immunization [24,26]. Gruber et
l. found that children with higher immunization coverage
eemed to acquire transient protection against development
f atopy in the first years of life [26]. In contrast, Hurwitz
nd Morgenstern suggested that diphtheria/pertussis/tetanus
DTP) immunization appeared to be associated with an
ncreased risk of subsequent asthma or other allergies
24].
Two different types of pertussis vaccine have been em-
loyed in infant immunization programmes. The whole-cell
ertussis vaccine (Pw) consists of heat/formalin inactivated
irulent whole bacteria whereas the pertussis acellular vac-
ine (Pa) is composed of purified components of the bacteria
Pa), typically including inactivated pertussis toxin. Pw im-
unization has a high efficacy and is associated with the
nduction of antigen-specific Th1 cells [21,27,28], but has
een associated with reactogenicity. In contrast Pa immu-
ization induces a mixed Th1/Th2 response in children and
n murine models, but has reduced reactogenicity [29]. It has
een suggested that promotion of allergy may occur directly,
y administering potentially pro-allergic vaccines, or indi-
ectly, by hindering the Th1-promoting effect of infectious
gents. Pertussis vaccination acts as an adjuvant for antigen-
pecific responses in laboratory animals [30]; active pertussis
oxin, is known to enhance immunoglobulin E (IgE) forma-
ion in animal models [31] and has been linked with a shift
oward Th2-like cytokines in humans [32,33].
Infection withB. pertussismodulates allergen priming and
he severity of airway pathology in a murine model of al- P
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f Health and the research ethics committee of the Na-
ional University of Ireland Maynooth. The experimental
pproach is outlined in Table 1, briefly groups of mice
ere immunized with whole-cell pertussis vaccine (Pw),
nfected with B. pertussis, and then sensitised to ovalbu-
in (OVA) at the peak of infection as detailed below. Con-
rol mice received similar treatment in which 0.9% (w/v)
aq) NaCl (hereafter termed Saline) replaced experimental
reatment.
.2. Immunization, sensitization and airway delivery of
VA
Four groups of at least thirty-five 6–8-week-old female
ALB/c mice (Pw, PwBp, PwOVA and PwBpOVA) were
mmunized i.p. with 0.16 I.U. of whole-cell pertussis vaccine
Pw) (Third International Standard, 1998, pertussis whole-
ell vaccine, NIBSC, UK), equivalent to 1/25th of the hu-
an dose according to the schedule outlined in Table 1. At
day mice were infected with B. pertussis, selected groups
ere then sensitized with ovalbumin (OVA). Sensitization
nvolved 100g OVA (Grade V; Sigma, Dorset, UK) emul-
ified in Alhydrogel® adjuvant (Superfos Biosector, Swe-
en) (1 mg/mouse aluminium hydroxide) administered as
.2 ml i.p. at 10 and 24 days. Control group (Ctrl) received
aline alone (i.p.). On 35, 36, and 37 days, PwOVA and
wBpOVA sensitized mice received 10l containing 50g
VA intra-nasally (i.n.) whereas remaining groups received
aline only (Table 1). All experiments were repeated at least
wice.
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Table 1
Experimental design
Time (days)
−42 −14 0 10 24 35/36/37
Groupa
Pw Pw Pw Saline aerosol Saline (i.p.) Saline (i.p. and i.n.) Saline (i.n.)
Pw and B. pertussis infection
(PwBp)
Pw Pw B. pertussis aerosol infection Saline (i.p.) Saline (i.p. and i.n.) Saline (i.n.)
Pw and OVA sensitization
(PwOVA)
Pw Pw Saline aerosol OVA (i.p.) OVA (i.p and i.n.) OVA (i.n.)
Pw, B. pertussis infection and
OVA sensitization (PwBpOVA)
Pw Pw B. pertussis aerosol infection OVA (i.p.) OVA (i.p and i.n.) OVA
Groupb
Control (Ctrl) Saline (i.p.) Saline (i.p.) Saline aerosol Saline (i.p.) Saline (i.p. and i.n.) Saline (i.n.)
B. pertussis infection (Bp) Saline (i.p.) Saline (i.p.) B. pertussis aerosol infection Saline(i.p.) Saline (i.p. and i.n.) Saline (i.n.)
OVA sensitization (OVA) Saline (i.p.) Saline (i.p.) Saline aerosol OVA (i.p.) OVA (i.p and i.n.) OVA (i.n.)
B. pertussis infection and OVA sen-
sitization (BpOVA)
Saline (i.p.) Saline (i.p.) B. pertussis aerosol infection OVA (i.p.) OVA (i.p and i.n.) OVA (i.n.)
a Groups of 6–8-week-old female BALB/c mice were immunized (i.p.) and boosted with whole-cell pertussis vaccine (Pw) at−42 and−14 days. On 0 day,
mice were either sham infected or infected with B. pertussis (Bp) by aerosol. At 10 and 24 days selected groups were sensitised to OVA by i.p alone or i.p and
i.n. routes, respectively. On 35, 36 and 37 days mice were exposed to either saline or OVA by the i.n. route (i.e. 25, 26, and 27 days post-OVA priming and after
bacterial clearance). Bacterial burdens in the airways were measured between 0 and 37 days. All other readouts, including plethysmography were performed
at 37 days.
b For comparison, further groups of unimmunized (sham immunized) mice were treated as follows: control (Ctrl) mice were sham infected on 0 day and
sham sensitised with saline. A second group (Bp) were infected with B. pertussis at 0 day and sham sensitized. The third group (OVA) were sham infected
but sensitized with OVA (100g, i.p.) at 10 and 24 days and again (50g i.n.) at 24, 35, 36, and 37 days. A separate group (BpOVA) were infected with
B. pertussis on 0 day, and sensitized as above. Each experiment was repeated at least twice, on each occasion n> 35 mice per group, bacterial burdens were
measured between 0 and 37 days, all other readouts were at 37 days.
2.3. B. pertussis aerosol infection159
Respiratory infection was initiated by aerosol challenge160
with B. pertussis strain W28, following growth under agita-161
tion conditions at 37 ◦C in Stainer-Scholte liquid medium.162
Bacteria from a log-phase culture were resuspended at a con-163
centration of 2× 1010 CFU/ml in 1% (w/v) casein in 0.9%164
(w/v) saline. The challenge inoculum was administered to165
groups of mice on 0 day (Bp, PwBp and PwBpOVA groups).166
Administration was by aerosol over a period of 15 min using167
a nebulizer. Groups of four or more mice were killed at vari-168
ous time points after aerosol challenge to assess the number169
of viable B. pertussis in the lungs. Remaining mice received170
a similar aerosol of sterile saline alone.171
2.4. Enumeration of viable bacteria in the lungs172
Lungs were removed aseptically into 1 ml of sterile phys-173
iological saline with 1% casein. Hundred microlitres of seri-174
ally diluted homogenate from individual lungs were placed175
onto triplicate Bordet-Gengou agar plates and the number of176
CFU determined after incubation at 37 ◦C for 4 days. Re-177
sults are reported as the mean number of B. pertussis CFU178
(±S.E.M.) for individual lungs, each determined in triplicate,179
from four or more mice per time point. All experiments were180
repeated twice.181
2182
183
c184
and aspiration of 0.5 ml PBS per mouse. This was pooled 185
from five mice (total 2.5 ml) per experimental group. All ex- 186
periments were performed at least twice. Diluted BALF was 187
assessed for the presence of cytokines. 188
2.6. Measurement of OVA and B. pertussis-specific 189
antibody 190
OVA and B. pertussis-specific IgG1, 2a, 2b, and 3 present 191
in collected sera were measured on day 37 by ELISA as pre- 192
viously described [35,36]. Total and OVA-specific IgE was 193
measured using a rat anti-mouse IgE monoclonal antibody 194
(BD, Pharmingen, San Diego, CA, USA). The IgE concen- 195
tration was expressed as g/ml after comparison to murine 196
IgE standards. 197
2.7. T-cell proliferation assays 198
Spleen cells (2× 106/ml) from infected, sensitized and 199
control mice (n= 4 or more per group) were tested for 200
in vitro proliferation against heat-inactivated B. pertussis 201
(1× 104 CFU/ml), OVA (20g/ml), Concanavalin A (Con 202
A) (5g/ml, positive control), or medium alone (negative 203
control). After 72 h, cell proliferation was assessed by liquid 204
scintillation counting of [3H]-thymidine incorporation and 205
results were expressed as mean CPM of triplicate wells±S.E. 206
A 207
c 208
t 209
f 210UN
CO
.5. Bronchoalveolar lavage
Bronchoalveolar lavage fluids (BALF) were obtained by
annulation of the trachea followed by repeat administrationIMLET 4082 1–10
t the 72 h time point, culture supernatants were sampled for
ytokine analysis, although the kinetics of cytokine produc-
ion varies this time point has previously proved acceptable
or detection of most cytokines [22].
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2.8. Cytokine measurement211
Concentrations of IL-5, IL-10, IL-13 and IFN- from212
spleen, and BALF were assessed by ELISA (BD, Pharmin-213
gen, San Diego, CA, USA). Cytokine concentrations were214
calculated by comparison with known cytokine standards as215
previously described [35], all determinations were made in216
triplicate, results are presented as mean cytokine concentra-217
tion (±S.E.M.).218
2.9. Whole body plethysmography219
Airway responsiveness on 37 days was assessed by metha-220
choline (MCh) induced airflow obstruction from conscious221
mice using whole-body plethysmography (Buxco Electron-222
ics, Sharon, CT, USA) as previously described [37]. Pul-223
monary airflow obstruction was measured by enhanced pause224
(PenH), a value determined from the ratio of expiratory time225
and relaxation time to peak expiratory flow and peak inspi-226
ratory flow and thought to correlate with airway responsive-227
ness. Measurements were obtained after exposure of mice228
for 3 min to PBS (baseline) followed by incremental doses229
(3.3 mg–50 mg/ml) of MCh delivered by aerosol [38].230
2.10. Respiratory tract histology231
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Fig. 1. Course of B. pertussis infection in experimental and control mice.
Groups of mice were sacrificed at intervals after challenge and the number
of viable bacteria estimated by performing colony counts on individual lung
homogenates. Results are representative from two experiments and are pre-
sented as mean (±S.E.M.) CFU in the lungs, determined individually from
four mice at each time point, and for each experimental group. Data for Ctrl
and OVA groups have been offset from zero for clarity.
tussis infection and Pw immunization induce a powerful Th1 256
response [29]. In order to examine immune cross-regulation 257
and potential interference with immunization, we tested the 258
effect of OVA sensitization upon the development of a pro- 259
tective response to infection in Pw immunized and non- 260
immunized mice. Mice received combinations of OVA sen- 261
sitization, Pw immunization and aerosol challenge with vir- 262
ulent B. pertussis (Table 1). Groups of mice infected with 263
B. pertussis (Bp and BpOVA) showed similar kinetics of 264
bacterial clearance (Fig. 1), indicating that OVA sensitiza- 265
tion does not influence bacterial clearance rates. Likewise, 266
OVA sensitized and non-sensitized mice that had been im- 267
munized prior to bacterial challenge (PwBpOVA and PwBp, 268
respectively) showed identical kinetics of clearance. No bac- 269
teria were recovered from the OVA sensitised or control 270
(Ctrl) groups, which were uninfected but received saline by 271
aerosol (Fig. 1). The bacterial burden in the Bp and BpOVA 272
groups peaked at 10 days and declined thereafter. Pw im- 273
munized mice cleared subsequent infection by B. pertus- 274
sis by 7 days. In contrast unimmunized mice (Bp and the 275
BpOVA groups) only showed complete bacterial clearance 276
by 35 days (Fig. 1). Therefore sensitization with OVA did 277
not impair vaccine-mediated clearance of B. pertussis in this 278
model. 279
3.2. OVA-specific IgE production is modulated by Pw 280
i 281
282
P 283
s 284
p 285
s 286
I 287UN
CO
RR
EC
TE
Animals (n= 5 per group per experiment) were sacrificed
t 37 days. Lungs were removed, fixed in a paraformalde-
yde/lysine/periodate fixative, paraffin embedded, sectioned
nd stained using the haematoxylin and eosin (H&E), Dis-
ombes (identification of eosinophils), alcian blue (iden-
ification of mucus), PAS (assessment of basement mem-
rane thickness), azure-A (identification of mast cells) and
an Gieson (identification of fibrosis) methods. Histopatho-
ogical changes evident were graded according to a semi-
uantitative scoring system as mild, moderate or severe by
wo researchers without prior knowledge of the treatment
roup using a previously established scoring system [17].
ll experiments were performed at least twice.
.11. Statistical methods
Results are expressed as the mean±S.E.M. of the indi-
ated number of animals. A Student’s t-test was used to deter-
ine significance among the groups. A value of P< 0.05 was
onsidered significant. Analyses were performed using the
raph-Pad PrismTM software (GraphPad, San Diego, CA).
. Results
.1. Ovalbumin sensitization does not impair
accine-mediated clearance of B. pertussis
The murine OVA model of airway hyperresponsiveness
nduces a powerful Th2 response [7] whereas both B. per-IMLET 4082 1–10
mmunization
The goal of this study was to examine the influence of
w immunization on responses associated with allergic sen-
itization. Although OVA-induced sensitization does not im-
air vaccine-mediated clearance of B. pertussis, it was pos-
ible that Pw influenced allergic sensitization. OVA-specific
gG was not detected from mice infected with B. pertussis
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Fig. 2. Serum IgE and IgG subclasses elicited by Pw vaccination, bacterial infection and allergic sensitization. (A) B. pertussis or (B) OVA-specific serum
antibody responses by IgG subclasses elicited in whole-cell B. pertussis (Pw), vaccinated plus Bp infection (PwBp), vaccinated plus sensitized (PwOVA),
or in mice vaccinated then infected with B. pertussis prior to sensitization (PwBpOVA), response from mice that received OVA sensitization alone (OVA)
or combined with infection (BpOVA) are shown for comparison. (C) B. pertussis-specific serum IgE and (D) OVA-specific serum IgE present from each
experimental group. Results are representative of two experiments expressed as geometric mean titre or ng/ml of antibody (±S.E.M.) from four animals each
determined independently in triplicate. *P< 0.05 compared to the PwOVA treated group.
only; similarly B. pertussis-specific IgG could not be de-288
tected in OVA sensitized animals, suggesting no significant289
cross-reaction between the two immunogens (Fig. 2A and290
B). An analysis of the serum antibody subclasses evoked291
revealed that Pw predominantly induced pertussis-specific292
IgG2a (Fig. 2A) as previously reported [28,34]. IgG2a re-293
mained the dominant subclass of pertussis-specific anti-294
body when Pw immunization was combined with OVA sen-295
sitization (PwOVA) or B. pertussis infection (PwBp) al-296
though IgG1 and IgG3 was detected in the latter groups297
(Fig. 2A). Pw immunization prior to OVA sensitization298
(PwOVA) did not significantly alter the dominant OVA-299
specific IgG1 response. Infection of these mice with B. per-300
tussis (PwBpOVA) did not broaden the subclasses of OVA-301
specific antibody detected although the titer was increased302
(Fig. 2B). Taken together, these data indicate that Pw im-303
munization does not modulate serum IgG subclasses in-304
duced by allergic sensitization. In contrast to the conser-305
vative effects on serum IgG subclasses, significant differ-306
ences were observed in the induction of IgE (Fig. 2C and307
D). Pw induces little B. pertussis-specific IgE, and this is308
not altered by OVA sensitization or infection (Fig. 2C).309
OVA sensitization induces high levels of OVA-specific IgE310
but this is significantly reduced by prior Pw immunization311
(Fig. 2D). However, a combination of immunization and in-312
fection prior to OVA sensitization resulted in a significant re-313
d314
g315
3.3. Pw immunization prevents B. pertussis 316
enhancement of OVA-induced IL-10 and IL-13 317
B. pertussis infection enhances OVA-induced IL-10 and 318
IL-13 [17]. Pw immunization has hitherto been regarded as 319
inducing essentially similar immune responses to those in- 320
duced by infection [22]. In order to dissect the influence of 321
immunization on airway hyperresponsiveness, we examined 322
cell-mediated immune responses in the various study groups. 323
Pw immunization alone or in combination with B. pertussis 324
infection (Pw or PwBp) induced very little IL-5 but strong 325
IFN- responses (Fig. 3A and B). This was consistent with 326
the protection observed earlier (Fig. 1) and previous data 327
[34]. Pw immunization reduced levels of IL-5, IL-13 and 328
IFN- (Fig. 3A–C) in all immunized groups suggesting that 329
Pw immunization prevents live B. pertussis enhancement of 330
these indices; mirroring the reduction in OVA-specific IgE 331
(Fig. 2D). Interestingly, previous results have shown that B. 332
pertussis infection induced specific IL-10 as well as IL-13 333
responses [17]. Here we demonstrate that in contrast to in- 334
fection, Pw-immunization resulted in significantly reduced 335
levels of IL-10, and IL-13 (Fig. 3A–D). 336
To extend these findings, we examined the levels of cy- 337
tokines present in bronchoalveolar lavage fluid (BALF) from 338
each group of mice. Pw immunization alone induced little or 339
no detectable cytokines in BALF. As expected, OVA sensiti- 340
z 341
o 342UN
COuction of IgE (P< 0.05) (Fig. 2D) compared to the PwOVAroup.IMLET 4082 1–10
ation induced high levels of IL-5, -10 and -13 but the levels
f IL-10 and -13 in particular, known to rise in infected mice,
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Fig. 3. Cell mediated immune responses from spleen, elicited by Pw vaccination, bacterial infection and allergic sensitization. IL-5 (A), IFN- (B), IL-13 (C) and
IL-10 (D) responses from spleen cell cultures stimulated with medium alone (−ve control, horizontal shading), heat inactivated B. pertussis at 1× 104 CFU/ml
(hatched bar), OVA (open bar) or Con A (+ve control, black bar). Responses are representative of duplicate experiments each performed in triplicate on
individual samples from four mice per group and are expressed as mean (±S.E.M.). *P< 0.05 compared to the PwOVA treated group.
were reduced in immunized mice that had been infected with343
B. pertussis (PwBpOVA) (Fig. 4A–D).344
3.4. Pw immunization prior to B. pertussis infection345
decreases bronchial hyperresponsiveness to sensitizing346
antigen347
It has been proposed that prior Th1 responses to bacte-348
rial infections protect against allergic disease however, Th1-349
inducing B. pertussis infection exacerbates airway hyperre-350
sponsiveness in OVA sensitized mice. It might be predicted351
that Pw, which induces a very similar immune response to B.352
pertussiswould have a similar exacerbating influence. In fact,353
this is not the case. We used whole body plethysmography as354
a surrogate measure of airway reactivity in mice immunized355
with Pw and infected with B. pertussis prior to OVA sensiti-356
zation (Fig. 5). Prior immunization with Pw does not enhance357
but protects against B. pertussis exacerbated airway hyperre-358
sponsiveness in comparison to controls. Statistical analysis359
using two-way analysis of variance (ANOVA) showed that360
mice vaccinated with Pw, and sensitized to OVA following361
B. pertussis infection (PwBpOVA) displayed significantly re-362
duced bronchial hyperreactivity compared to BpOVA sensi-363
tized animals (P< 0.05) (Fig. 5D). Thus demonstrating that 364
vaccination with Pw protects against B. pertussis exacerba- 365
tion of allergic asthma. 366
B. pertussis infection is known to modulate the quality 367
of the inflammatory influx of the respiratory tract, with a 368
marked reduction in eosinophil numbers accompanied by 369
varying degrees of epithelial hyperplasia, mucus metaplasia, 370
and airway pathology [17]. Lung tissue was assessed histo- 371
logically (Table 2). Minimal pathology was observed in mice 372
immunized with Pw or those immunized and infected with 373
B. pertussis (PwBp) (Fig. 6A and B). Pw and OVA sensitized 374
(PwOVA) mice illustrated moderate mural and peri-airway 375
inflammation with accompanying mild mucus metaplasia and 376
moderate hyperplasia of the epithelium (Fig. 6C). The com- 377
bination of Pw immunization,B. pertussis infection and OVA 378
sensitization did not show enhanced pathology but only mod- 379
erate mucus metaplasia and moderate hyperplasia of the ep- 380
ithelium (Fig. 6D). Given that previous work has shown that 381
B. pertussis infection in combination with OVA sensitization 382
(BpOVA) displayed more severe airway inflammation with 383
a greater degree of both epithelial hyperplasia and mucous 384
metaplasia, it can be clearly seen here that Pw immuniza- 385
tion reduces the severity of airway pathology (Fig. 6D) and 386UN
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Fig. 4. Pw immunization modulates the local cytokine response to B. pertussis infection and OVA sensitization. Diluted BALF (0.5 ml per mouse) was pooled
from five mice per group and concentrations of IL-5 (A), IFN- (B), IL-13 (C) and IL-10 (D) were determined by EIA. Results are representative of duplicate
experiments. Cytokine concentrations were assayed in triplicate with values expressed as mean cytokine concentration in diluted BALF (±S.E.M.). *P< 0.05
compared to the PwOVA treated group.
reduces pulmonary resistance as indicated by plethysmogra-387
phy (Fig. 5D).388
4. Discussion389
The present study demonstrates that Pw immunization390
protects against B. pertussis exacerbation of OVA-induced391
Table 2
Histological assessment of airway pathology
Treatment group Mucous metaplasia of
airway epithelium
Hyper-plasia of airway
epithelium
Smooth muscle
hypertrophy of airway wall
Peri-airway/vascular
inflammationa
Overall degree E N L M F
Ctrl − − − − − − − − −
Bp − + + + − + ++ − −
Ova ++ ++ ++ ++b + ++ ++c − −
BpOVA +++ +++ ++ +++b ++ +++ +++c − −
Pw − − − − − − − − −
PwBp − + + − − − − − −
PwOVA + ++ + ++b ++ ++ ++c − −
PwBpOVA ++ ++ ++ ++b ++ ++ ++c − −
A semi-quantitative score (− absent, + mild, ++ moderate, +++ severe) was assigned to features of airway pathology observed according to previously described
criteria [17].
a Peri-airway/vascular inflammation was assessed in terms of overall degree and of numbers of infiltrating eosinophils (E), neutrophils (N), lymphocytes,
plasma cells and macrophages (L), mast cells (M) and in terms of circumscribing fibrosis (F).
b Inflammation extending into surrounding pulmonary interstitium and alveolar spaces.
c Macrophage giant cells form part of inflammatory exudates within surrounding alveolar spaces.
airway hyperresponsiveness in a murine model. Pw immu- 392
nization suppresses antibody and cell mediated responses 393
against OVA sensitization in combination with B. pertussis 394
infection at both the local and systemic level, coupled with 395
a subsequent reduction in airway reactivity and pathology. 396
It has been previously shown that B. pertussis exacerbates 397
OVA-induced airway pathology leading to the development 398
of more pronounced allergen-induced airwayinflammationUN
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Fig. 5. Pw immunization prior to B. pertussis infection decreases bronchial hyperresponsiveness to sensitizing antigen. Airway hyperreactivity in response
to increasing concentrations of inhaled methacholine (MCh) was measured by whole-body plethysmography. (A) Control and Bp infected mice (B), Pw and
PwBp (C), OVA and PwOVA (D), BpOVA and PwBpOVA groups, respectively. Results are representative of two experiments (n= 4) and values are expressed
as mean enhanced pause (PenH)±S.E.M., in groups where no errors are visible, error bars are shorter than the size of the data point symbol.
[17]. We demonstrate that Pw immunization protects against399
this as well as reducing airway hyperresponsiveness.400
The prevalence of asthma and allergic disease has in-401
creased in many countries [39,40] and there has been spec-402
ulation as to possible causes [41,42], including the possible403
role of immunization in promoting allergic sensitization [43].404
For example, pertussis vaccination acts as an adjuvant for405
antigen-specific responses in laboratory animals [30,33]; a406
specific IgE response to pertussis toxin itself has been iden-407
tified in children receiving pertussis immunization [44]; and408
vaccination with some other organisms such as Haemophilus409
influenzae enhances histamine release in laboratory animals410
[45]. Active pertussis toxin has a similar effect [46]. In ad-411
dition, two studies have suggested that pertussis infection412
increased the risk of atopy [47,48]. It is therefore theoreti-413
cally possible that Pw immunization might contribute to the414
development of allergic disease.415
The goal of this study was to test whether immunization416
with whole-cell pertussis (Pw) vaccine would protect against417
B. pertussis exacerbation of allergic asthma. B. pertussis in-418
fection modulates allergen priming and the severity of airway419
pathology in a murine model[17]. It has been proposed that420
IL-10 plays an essential role in modulating the immune re-421
sponses by inducing towards regulatory T-cell responses[49]422
however Lee et al have demonstrated that IL-10 induces IL-13 423
production in vivo and that this is responsible for the mucus, 424
but not the inflammatory/fibrotic effects of IL-10 [50]. In 425
the present study, we observe that Pw immunization prevents 426
induction of IL-10 and IL-13 and protects against airway hy- 427
perreactivity. Although IL-10 is known to act in an immune 428
regulatory manner, we and others have suggested that it has 429
broader functions that may not always protect against inflam- 430
matory disease [17,51]. For example, Grunstein et al. have 431
suggested that IL-10 may play an important role in allergic 432
asthma by acting directly on the airway smooth muscle it- 433
self [51]. Previous studies in humans have demonstrated that 434
IL-13 mRNA and protein levels are elevated in the lungs of 435
atopic and non-atopic asthmatics [52] suggesting that over 436
expression of IL-13 may predispose toward the development 437
of both types of asthma [53]. The reduction in both IL-10 438
and IL-13 at the systemic and local levels suggests that by 439
removing the damaging effects of pertussis infection and con- 440
sequently reducing IL-10 and IL-13, Pw exerts a protective 441
effect. Interestingly, very recent work by Kim et al has shown 442
that components of B. pertussis can inhibit airway hyeperre- 443
sponsiveness [54]. That study demonstrated that unmethy- 444
lated CpG sequences from B. pertussis DNA inhibited Th2 445
cytokines in the airways via a TLR9 interaction [54]. Our 446UNIMLET 4082 1–10
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Fig. 6. Whole-cell B. pertussis vaccine reduces the severity of airway pathology to sensitizing antigen both in the presence and absence of B. pertussis
infection. Representative morphological changes at 37 days in transverse sections of bronchioles from (A) Pw immunized mice showing no changes evident;
(B) Pw/Bp mice, minimal changes evident; (C) Pw/OVA treated mice, illustrating moderate mural and peri-airway inflammation with accompanying mild
mucous metaplasia (blue staining goblet cells) and moderate hyperplasia of epithelium; (D) Combined Pw/Bp/OVA treated group, illustrating a moderate mural
and peri-airway inflammation, moderate mucous metaplasia and moderate epithelial hyperplasia; (E) OVA sensitized group illustrating moderate mural and peri-
airway inflammation with accompanying moderate mucus metaplasia (blue staining goblet cells) and hyperplasia of epithelium; (F) combined B. pertussis/OVA
treated group illustrating severe mural and peri-airway inflammation, moderate epithelial hyperplasia and severe mucous metaplasia with accompanying mucus
plugging of the lumen. All sections are representative of groups of five mice per experiment, performed at least twice. Sections stained with a combined
Discombe’s/Alcian blue stain, original magnification 400×.
observation of reduced inflammation and OVA-specific IgE447
(Figs. 2 and 6) in PwBpOVA mice is consistent with that448
finding. TLR9 mediated reduction in Th2 cytokines can be449
invoked in this situation, because although these mice will be450
exposed to bacterial DNA in a context where prior immuniza-451
tion will limit tissue damage or the other immunomodulatory452
effects of viable B. pertussis [17,54].453
The most common formulation of the hygiene hypothesis454
is based upon a lack of immunological stimuli in early in-455
fancy that results in aberrant Th2 responses [10,12]. Clearly456
infant pertussis immunization or infection could potentially457
influence this process. Studies in neonatal mice support our458
findings that Pw is a strong Th1 inducer, but it is less effective459
in inducing antibody responses during this period [28,55,56]. 460
A study by Gruber et al. revealed no evidence for an allergy 461
promoting effect of common childhood vaccines in a prospec- 462
tively followed atopy risk-enhanced birth cohort [26]. More- 463
over, they found that children with a better vaccination cov- 464
erage seemed to be better protected against the development 465
of atopy in their second and third years of life. In particu- 466
lar, measles/mumps, pertussis, and diphtheria/tetanus immu- 467
nization were associated with a transient reduction of atopy, 468
whereas immunization against polio and H. influenzae had 469
no effect. Furthermore, immunization of children with Pw 470
down regulated the IgE response to co-administered diphthe- 471
ria and tetanus toxoids [57]. In contrast, a study involving the 472
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effects of diphtheria–tetanus–pertussis (DTP) or tetanus vac-473
cination on allergies among children in the U.S. reported that474
DTP or tetanus vaccination appeared to increase the risk of475
allergies and related respiratory symptoms, one contentious476
interpretation of this study is that vaccine components may477
be responsible for a portion of the increased prevalence of478
asthma and allergies in U.S. children [24].479
We have established models that allow examination of the480
mechanisms of interaction between protective immunization481
and allergic sensitization. Pw immunization reduces IL-13482
and IL-10 in BALF (Fig. 4C and D) and also protects against483
airway hyperresponsiveness (Fig. 5D). These data indicate484
that although Pw induces a similar immune response to B.485
pertussis infection, these responses are not identical. Pw does486
not enhance airway IL-13 and consequently does not enhance487
but protects against the exacerbation of allergic responses. We488
find no evidence of Pw contributing to allergic asthma, but489
rather provide evidence of a mechanism whereby whole-cell490
pertussis vaccination has a protective role.491
Acknowledgments492
We thank Mrs. Sheila Worrell, Mr. Joseph Brady and Ms.493
Bernadette Ruane for their expert technical assistance. This494
work was supported by grants from the Irish HEA PRTL495
p496
T497
R498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
[519
[520
521
[522
[523
524
[525
526
[527
528
[16] Johnson TR, Graham BS. J Virol 1999;73:8485–95. 529
[17] Ennis DP, Cassidy JP, Mahon BP. Clin Exp Allergy 530
2004;34:1488–97. 531
[18] Holgate ST. Clin Exp Allergy 2000;30(Suppl 1):37–41. 532
[19] Holgate ST, Davies DE. Int J Biochem Cell Biol 2002;34:1520–6. 533
[20] Barnard A, Mahon BP, Watkins J, Redhead K, Mills KH. Immunol- 534
ogy 1996;87:372–80. 535
[21] Mahon BP, Ryan M, Griffin F, Mills KH. Biochem Soc Trans 536
1997;25, 341S. 537
[22] Mills KH, Ryan M, Ryan E, Mahon BP. Infect Immun 538
1998;66:594–602. 539
[23] Odent M, Culpin E. Lancet 2003;361:434. 540
[24] Hurwitz E, Morgenstern H. JMPT 2000;23:81–90. 541
[25] Brambleby P, Hanrahan J. Public Health 1989;103:289–94. 542
[26] Gruber C, Susanne L, Ulrich W, et al. Pediatrics 2003;111:282–7. 543
[27] Ryan M, Murphy G, Gothefors L, Nilsson L, Storsaeter J, Mills KH. 544
J Infect Dis 1997;175:1246–50. 545
[28] Mahon BP, Brady MT, Mills KH. J Infect Dis 2000;181:2087–91. 546
[29] Mills KH, Brady M, Ryan E, Mahon BP. Dev Biol Stand 547
1998;95:31–41. 548
[30] Pauwels RA, Van Der Straeten M, Platteau B, Bazin H. Allergy 549
1983;38:239–46. 550
[31] Lindsay DS, Partron R, Wardlaw AC. Int Arch Allergy Immunol 551
1994;105:281–8. 552
[32] Rook G, Zumla A. Lancet 1997;349:1831–3. 553
[33] Mu HH, Sewell WA. Immunology 1994;83:639–45. 554
[34] Mahon BP, Ryan MS, Griffin F, Mills KH. Infect Immun 555
1996;64:5295–301. 556
[35] Mahon BP, Sheahan BJ, Griffin F, Murphy G, Mills KH. J Exp Med 557
1997;186:1843–51. 558
[36] Morokata T, Ishikawa J, Ida K, Yamada T. Immunology 559
560
[ 561
[ 562
563
[ 564
[ 565
566
[ 567
[ 568
[ 569
[ 570
571
[ 572
573
[ 574
575
[ 576
577
[ 578
[ 579
580
[ 581
[ 582
583
584
[ 585
586
[ 587
588
[ 589
590
[ 591
592
[ 593
[ 594UN
CO
RR
EC
TE
rogramme (Darren Ennis). Bernard Mahon is a Wellcome
rust/HRB new blood fellow (GR 054236).
eferences
[1] Umetsu DT, McIntire JJ, Akbari O, Macaubas C, DeKruyff RH. Nat
Immunol 2002;3:715–20.
[2] Swain SL, Weinberg AD, English M, Huston G. J Immunol
1990;145:3796–806.
[3] Cho SH, Stanciu LA, Begishivili T, Bates PJ, Holgate ST, Johnston
SL. Clin Exp Allergy 2002;32:427–33.
[4] Wilder JA, Collie DD, Wilson BS, Bice DE, Lyons CR, Lipscomb
MF. Am J Respir Cell Mol Biol 1999;20:1326–34.
[5] Ying S, Humbert M, Barkans J, Corrigan CJ, Pfister R, Menz
G, Larche M, Robinson DS, Durham SR, Kay AB. J Immunol
1997;158:3539–44.
[6] Padrid PA, Mathur M, Li X, Herrmann K, Qin Y, Cattamanchi A,
Weinstock J, Elliott D, Sperling AI, Bluestone JA. Am J Respir Cell
Mol Biol 1998;18:453–62.
[7] Haczku A, Takeda K, Hamelmann E, Oshiba A, Loader J, Joetham
A, Irvin C, Kikutani H, Gelfand EW. Am J Respir Crit Care Med
1997;156:1945–55.
[8] Daser A, Meissner N, Herz U, Renz H. Curr Opin Immunol
1995;7:762–70.
[9] Erb K. Immunol Today 1998;7:317–22.
10] Strachan DP. Thorax 2000;55(Suppl 1):2–10.
11] Matricardi PM, Rosmini F, Riondino S, Fortini M, Ferrigno L,
Rapicetta M, Bonini S. Bmj 2000;320:412–7.
12] Strachan DP. Bmj 1989;299:1259–60.
13] Cembrzynska-Nowak M, Szklarz E, Inglot AD, Teodorczyk-Injeyan
JA. Am Rev Respir Dis 1993;147:291–5.
14] Hansen G, Berry G, DeKruyff RH, Umetsu DT. J Clin Invest
1999;103:175–83.
15] Matsuse H, Behera AK, Kumar M, Rabb H, Lockey RF, Mohapatra
SS. J Immunol 2000;164:6583–92. P
RO
IMLET 4082 1–10
1999;98:345–51.
37] Hamelmann E, Gelfand EW. Curr Protocols Immunol 1999.
38] Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin
CG, Gelfand EW. Am J Respir Crit Care Med 1997;156:766–75.
39] Huurre TM, Aro HM, Kaakkola JJ. J Asthma 2004;41:311–7.
40] Ronmark E, Lundback B, Jonsson E, Jonsson AC, Lindstrom M,
Sandstrom T. Allergy 1997;52:1071–8.
41] Bousquet J, Burney P. Clin Exp Allergy 1993;23:484–92.
42] Peat JK. Clin Exp Allergy 1994;24:797–800.
43] Shaheen S. Clin Exp Allergy 1995;25:1034–7.
44] Odelram H, Ganstrom M, Hedenskog K, Bjorksten B. Pediatr Al-
lergy Immunol 1994;5:118–23.
45] Schreurs AJ, Terpstra GK, Raaijmakers JA, Nijkamp FP. Eur J Phar-
macol 1980;62:261–8.
46] Van Meijeren CE, Vleeming W, De Wildt DJ, et al. Eur J Pharmacol
2004;493:139–50.
47] Wjst M, Dold S, Reitmeir P, Fritzsch C, von Mutius E, Thiemann
HH. Ann Allergy 1994;73:450–4.
48] Odent MR, Culpin EE, Kimmel T. JAMA 1994;272:592–3.
49] Zuany-Amorim C, Sawicka E, Manlius C, Le Moine A, Brunet LR,
Kemeny DM, Bowen G, Rook G, Walker C. Nat Med 2002;8:625–9.
50] Lee CG, Homer RJ, Elias JA, et al. J Biol Chem 2002;277:35466–74.
51] Grunstein MM, Hakonarson H, Leiter J, Chen M, Whelan R,
Grunstein JS, Chuang S. Am J Physiol Lung Cell Mol Physiol
2001;281:1130–7.
52] Naseer T, Minshall E, Hamid Q. Am J Respir Crit Care Med
1997;155:845–51.
53] Humbert M, Durham SR, Kay AB, Corrigan CJ, et al. J Allergy
Clin Immunol 1997;99:657–65.
54] Kim YS, Kwon KS, Kim DK, Choi IW, Lee HK. Immunology
2004;112:624–30.
55] Roduit C, Bozzotti P, Mielcarek N, Lambert PH, del Giudice G,
Locht C, Siegrist CA. Infect Immun 2002;70:3521–8.
56] Mahon BP. Curr Med Chem 2001;8:1057–75.
57] Gruber C, Lau S, Sommerfeld C, Wahn U, Aalberse RC. J Immunol
2001;167:2411–7.
